INDEPENDENT NEWS

nib New Zealand offers members genetic testing

Published: Thu 28 Feb 2019 09:37 AM
nib New Zealand offers members genetic testing to help treat ovarian cancer
Women with ovarian cancer can now access genetic testing services in the private health system to help determine their best course of treatment, following a first-ever partnership between nib New Zealand and the New Zealand Family Cancer Service.
This means nib members who are being treated in the private sector, can undergo genetic counselling and testing to help determine what’s best as they move through their treatment.
nib New Zealand Chief Executive Officer, Rob Hennin said genomic profiling is playing an increasing role in the treatment and management of cancer.
“We want to ensure our members have the best possible treatment to help them fight this insidious disease,” Mr Hennin said.
“It’s crucial in the management of cancer, for both public and private patients, that they access the best advice and treatment possible without too much delay,” he said.
nib paid almost $6 million in chemotherapy treatment claims on behalf of members over the 24 months to 2018. Health data shows that between 300 and 350 women are diagnosed with ovarian cancer each year in New Zealand.
Genetic testing allows medical practitioners to identify a patient’s Breast Cancer 1 Gene (BRCA) mutation status, which in turn, helps determine best options for treatment.
“If a patient carries a harmful BRCA mutation gene, they are likely to benefit from the addition of a type of treatment called PARP inhibitors, which can lower the risk of disease progression, or death, by as much as 70%,’ said doctors Peter Fong (Medical Oncologist) and Ai Ling Tan (Gynaecological Oncologist) from the New Zealand Family Cancer Service.
“Better survival rates are the key for patients. We know the right treatment can extend someone’s life, occasionally by as much as a handful of precious years,” Dr Fong said. “PARP inhibitors have also proven effectiveness in advanced breast cancer patients who carry the BRCA mutation.”
The agreement between nib and the New Zealand Family Cancer Service will also help women who do not currently meet the criteria for public regional genetic counselling to access those services in the private health system.
“We have a real opportunity to help women diagnosed with ovarian cancer fund their treatment and be a true health partner, ensuring they get the right treatment for their needs,” Mr Hennin said.
nib members whose policies include surgical cover can take up genetic testing for ovarian cancer throughout 2019, with the trial period to be reviewed at the end of the year.
ends

Next in Lifestyle

Budget 2019 funding recognises creative community
By: New Zealand Government
Auckland children to be vaccinated for measles at 12 months
By: Auckland Regional Public Health Service
Creative New Zealand welcomes Government’s new investment
By: Creative New Zealand
Oscar Kightley recipient of 2019 Pacific Writers' Residency
By: Fulbright NZ
Fulbright New Zealand announces 2019 grantee cohort
By: Fulbright NZ
Starship welcomes change in first MMR vaccination age
By: Starship
Nine measles cases now confirmed in Northland
By: Northland District Health Board
Tapu Te Ranga Marae tapu lifted, Community Service planned
By: Tapu-te-Ranga Trust and Marae
Statement from the Stewart Whānau of Tapu-te-Ranga Trust
By: Tapu-te-Ranga Trust and Marae
Tapu Te Ranga marae fire damage: Whānau plan for new chapter
By: RNZ
Update: Tapu Te Ranga Marae fire investigation
By: Fire and Emergency NZ
Fire at Tapu Te Ranga Marae, Island Bay, Wellington - update
By: Fire and Emergency NZ
View as: DESKTOP | MOBILEWe're in BETA! Send Feedback © Scoop Media